You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Low-Cost, Regenerable Air Filter for Efficient Gaseous Pollutants Removal

    SBC: Precision Combustion, Inc.            Topic: D

    Precision Combustion, Inc. (PCI) proposes to develop a regenerable, low-cost, high-efficiency pollution control technology for removal of gaseous pollutants from contaminated air streams. This innovative air filter technology will combine our novel proprietary Microlith® support elements with sorbent nanomaterials that can be tailored to capture a variety of targeted gaseous pollutants. Originall ...

    SBIR Phase I 2014 Environmental Protection Agency
  2. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Formulation of LbL microparticle vaccine in microneedle array for intradermal del

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Practical high resolution microscopy of un-cut, un-embedded lung biopsies

    SBC: Applikate Technologies LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This aim of this Phase I SBIR proposal from Applikate Technology, LLC, is to validate the use of ClearView, a novel approach to performing complete and non-destructive imaging of tissue specimens, for primary pathologyof lung biopsies. Error rates for diagnoses of lung cancer from biopsies may run as high as 15%. Although the root causes of errors are diverse, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Engineered Neurotensin Fragments Targeting Neuropathic Pain

    SBC: JT Pharmaceuticals, Inc.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a lasmiditan analogue for treatment of acute kidney injury

    SBC: Mitohealth, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Sterculic Acid Analogs to Inhibit Macular Degeneration

    SBC: L2 Diagnostics, LLC            Topic: NEI

    ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Hydrocyanine Probes for the Accurate Detection of Reactive Oxygen Species

    SBC: LI-COR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Reactive oxygen species (ROS) are involved in numerous cell-signaling pathways. They have been implicated in over 150 diseases including cancer, arthritis, Parkinson's disease, diabetes, myocardial infarction and atherosclerosis. The need to understand the role of ROS in these processes is evidenced by the 80,000 publications in this field during the last ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Lessons from Nature: Antifreeze Glycolipids for Cryopreservation of Mammalian Cel

    SBC: Cell & Tissue Systems, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Storage of cells for many researchers simply involves addition of 10% DMSO or similar cryoprotectants to cells in suspension, putting them in cryovials and slow cooling to subzero temperaturesf and storage in a mechanical or nitrogen cooled freezer or dewar. As long as viable cells are present upon thawing, cell yield may be a secondary consideration due to the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government